Urinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data
Project Oncology®Urinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data
Charles Turck, PharmD, BCPS, BCCCP
Petros Grivas, MD, PhD
ctDNA-Guided Adjuvant Atezolizumab in MIBC: IMvigor011 Insights
Project Oncology®ctDNA-Guided Adjuvant Atezolizumab in MIBC: IMvigor011 Insights
Charles Turck, PharmD, BCPS, BCCCP
Guru P. Sonpavde, MD
Redefining First-Line Therapy in mCSPC: Applying Evidence in Practice
Project Oncology®Redefining First-Line Therapy in mCSPC: Applying Evidence in Practice
Brian P. McDonough, MD, FAAFP
William Oh, MD
ctDNA-Guided Bladder Preservation in Muscle-Invasive Bladder Cancer
Project Oncology®ctDNA-Guided Bladder Preservation in Muscle-Invasive Bladder Cancer
Charles Turck, PharmD, BCPS, BCCCP
Pooja Ghatalia, MD
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
On the Frontlines of Prostate CancerNew Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
Wayne Kuang, MD
William Oh, MD
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
On the Frontlines of Prostate CancerWhy Words Matter: Rethinking Terminology in Advanced Prostate Cancer
William Oh, MD
- advertisement
Shifting the Script: Personalizing Overactive Bladder Treatment in Complex Patients
CME/CEShifting the Script: Personalizing Overactive Bladder Treatment in Complex Patients
David Staskin, MD
Matt T. Rosenberg, MD
Kennedy Koebbe, MSN, RN
Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
CME/CEExpert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
Neal Shore, MD, FACS
Sarah Psutka, MD, MS
Patient-Centric ADT Intensification in Hormone-Sensitive Prostate Cancer: Balancing Efficacy, Safety, Quality of Life, and Survival
CME/CE Broadcast ReplayPatient-Centric ADT Intensification in Hormone-Sensitive Prostate Cancer: Balancing Efficacy, Safety, Quality of Life, and Survival
Mary-Ellen Taplin, MD
Ignacio Duran, MD
Wenxin Xu, MD
Sandy Srinivas, MD
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
MinuteCE®Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Ignacio Duran, MD
Wenxin Xu, MD
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
MinuteCE®Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
Ignacio Duran, MD
Sandy Srinivas, MD
- advertisement